Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of vilobelimab versus placebo for ulcerative pyoderma gangrenosum
NL-OMON58658Phase 3Completed
- Sponsor
- InflaRx
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pyoderma gangrenosum (PG) comparing Vilobelimab with Placebo (2 arms). Primary endpoint: Complete closure of target ulcer up to end of treatment. Started Nov 2023; status: completed.
02
Drugs
vilobelimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NL-OMON58658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58658.